Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics.

Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA.

Nicotine Tob Res. 2009 Jul;11(7):859-67. doi: 10.1093/ntr/ntp077. Epub 2009 May 29.

2.

Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial.

Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, Hurt RD.

JAMA. 2014 Jan 8;311(2):155-63. doi: 10.1001/jama.2013.283185.

3.

Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.

Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, Fiore MC, Rennard SI, Leischow SJ.

Clin Ther. 2001 May;23(5):744-52.

PMID:
11394732
4.

Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.

Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, Tyndale RF, Okuyemi KS, Ahluwalia JS.

J Natl Cancer Inst. 2012 Feb 22;104(4):290-8. doi: 10.1093/jnci/djr513. Epub 2012 Jan 25.

5.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
6.

Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study.

Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, O'Connor K.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):111-8. doi: 10.1016/j.drugalcdep.2011.03.005. Epub 2011 Apr 19.

7.

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD.

Ann Intern Med. 2001 Sep 18;135(6):423-33.

PMID:
11560455
8.

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.

Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE.

Lancet. 2016 Jun 18;387(10037):2507-20. doi: 10.1016/S0140-6736(16)30272-0. Epub 2016 Apr 22.

PMID:
27116918
9.

Changes in health-related quality of life with smoking cessation treatment.

Hays JT, Croghan IT, Baker CL, Cappelleri JC, Bushmakin AG.

Eur J Public Health. 2012 Apr;22(2):224-9. doi: 10.1093/eurpub/ckq137. Epub 2010 Sep 30.

PMID:
20884658
10.

Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.

Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS.

JAMA. 2002 Jul 24-31;288(4):468-74.

PMID:
12132977
11.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group..

JAMA. 2006 Jul 5;296(1):47-55.

PMID:
16820546
12.

Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.

Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G.

Addiction. 2004 Sep;99(9):1206-18.

PMID:
15317642
13.

A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.

Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.

J Clin Psychopharmacol. 2007 Aug;27(4):380-6.

PMID:
17632223
14.

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group..

JAMA. 2006 Jul 5;296(1):56-63. Erratum in: JAMA. 2006 Sep 20;296(11):1355.

PMID:
16820547
15.

Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.

Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Rowland KM, Bernath A, Loots ML, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL.

Mayo Clin Proc. 2007 Feb;82(2):186-95.

PMID:
17290726
16.
17.

A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling.

McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, Baker TB.

Nicotine Tob Res. 2008 Apr;10(4):717-29. doi: 10.1080/14622200801968343.

PMID:
18418793
18.

Triple-combination pharmacotherapy for medically ill smokers: a randomized trial.

Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, Carson JL.

Ann Intern Med. 2009 Apr 7;150(7):447-54.

PMID:
19349630
19.

Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome.

Hurt RD, Wolter TD, Rigotti N, Hays JT, Niaura R, Durcan MJ, Gonzales D, Sachs DP, Johnston JA, Offord KP.

Addict Behav. 2002 Jul-Aug;27(4):493-507.

PMID:
12188588
20.

Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports.

Patten CA, Rummans TA, Croghan IT, Hurt RD, Hays JT.

J Clin Psychiatry. 1999 Jul;60(7):436-41.

PMID:
10453796

Supplemental Content

Support Center